Fast Locator 2011-2012: Xcelience, LLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Xcelience, LLC



Xcelience is a premier provider of formulation development and manufacturing solutions with a solid reputation for accelerating early phase small molecule development. Our outstanding quality record, significant drug development expertise, willingness to customize, and disciplined project management enable us to deliver real advantage to clients with the need to speed potential drugs to clinical trials.

Since 1997, Xcelience has been renowned for reliably expediting drug product development for oral solid, semi-solid and liquid dosage forms. Our formulation development scientists have considerable experience overcoming challenging associated with physical and chemical properties of drug substance, or limited quantities of active pharmaceutical ingredient (API), in a manner that results in compounds with improved solubility and bioavailability. Xcelience operates out of a cGMP compliant, FDA audited, DEA licensed facility in Tampa, Florida.

Xcelience is more than just the market leader for powder-in-capsule services, which enable clients to fill very small amounts of API into capsule and reduce time to first-in-human studies by as much as 45% relative to traditional drug development programs, we are a full spectrum formulation development and manufacturing provider. Our recently expanded process technology capabilities reflect our continued commitment to help clients build towards improved manufacturing outcomes in a manner consistent with the FDA’s Quality by Design initiative.


Regions where services are provided:

North America and Europe


Outsourcing serivces provided:

Development and Phase I/IICTM

  • Solid dose, semisolids, and liquids development
  • Process development-small molecule

Analytical Services

  • Chemistry and stability
  • Particle characterization

Packaging and Logistics

  • Clinical labels
  • Clinical packaging and distribution

Contact:

Partnering with a specialist like Xcelience for early phase development can reduce product risk and accelerate drug development timelines. For more information, contact Xcelience at 608.643.4444 or visit www.xcelience.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here